INTRODUCTION
The glycoprotein complex Factor VIII-von Willebrand Factor (FVIII-vWF) plays a major role in hemostasis (1) . It consists of two components, namely the von Willebrand Factor (vWF) and factor VIII-C (FVIII-C). The two components have distinct biological properties in hemostasis. FVIII-C is a clotting factor which has an essential function in the intrinsic coagulation pathway, whereas vWF promotes the adherence of platelets to the subendothelium after vascular injury (2) (3) (4) . FVIII-vWF circulates in plasma as a series of multimers with a relative mass (M ) of 0.8-20x106 (1, 5) . The constituent unit of vWF is a glycoprotein with a Mr of 225 000 which is synthesized by vascular endothelial cells as a precursor protein of about 260 000 (6) (7) (8) . The precursor protein is apparently processed during secretion into the lumen to the mature vWF protein (8, 9) . Assembly of the mature protein into large aggregated forms is a prerequisite for its biological function. Furthermore, vWF is considered to be the carrier protein for the procoagulant activity and apparently modulates its turnover (10) .
A defective or absent vWF protein results in a bleeding disorder known as von Willebrand's disease which afflicts about 10 individuals per 100 000 people. A substitution therapy with plasma or cryoprecipitate is often adequate, but is hampered by the potential presence of infectious agents in the plasma preparations (11, 12) . These problems can be circumvented by using vWF protein made by recombinant DNA techniques. Such a product may also be necessary to reconstruct a stable FVIII-C preparation made by these techniques for the treatment of hemophilia-A patients (13, 14) . Cloning of the cDNA is the first step towards the production of recombinant vWF. A vWF cDNA will also enable us to study the structure and function of the vWF protein. Furthermore , it offers us the possibility to determine the chromosomal location of the vWF gene and analyze the structure of the vWF gene of both normal individuals and of patients with von Willebrand's disease.
MATERIALS AND METHODS DNA analysis Plasmid DNA isolations, isolation of genomic DNA, analysis of restriction enzyme-digested DNA on agarose or polyacrylamide gels, Southern and Northern blotting and radiolabeling of DNA by "nick translation" was done as described (15) . DNA sequencing was carried out by the dideoxy chain-termination procedure (16) .
Cell cultures Endothelial cells were isolated from veins of human umbilical cords according to Jaffe et al. (17) with some modifications (18) . Cells used for RNA isolation had received three or four passages and reached confluency before harvesting. After trypsinization, the cells were washed with 10 mM sodium phosphate (pH 7.4), 0.14 M NaCl and frozen in liquid nitrogen until used. Isolation of endothelial polyA RNA Total RNA was prepared from about 2x109 endothelial cells, by the "hot phenol" procedure (19) with the following modifications. Lysis of the cells was done in the presence of 10 mM vanadyl ribonucleoside complex to prevent RNA degradation. Furthermore, contaminating DNA was removed by a selective precipitation of RNA in 3.3 M LiCl for 30 min at o0C. PolyA RNA was isola-ted after two cycles of adsorption to and elution from oligo-(dT) cellulose (20) . The yield of polyA RNA from 2x1O9 endothelial cells was approximately 300 pg. The polyA RNA preparation was judged to be relatively undegraded, since it programmed the synthesis of discrete, long polypeptides in an in-vitro rabbit reticulocyte lysate. Size fractionation of polyA RNA PolyA RNA was size-fractionated by preparative urea-agarose gel electrophoresis according to the procedure of Rosen et al. (21) except that low melting agarose (1.5%) was used. After electrophoresis, the gel was cut into slices and RNA fractions were extracted as described (22) . Alternatively, polyA RNA was fractionated according to its size by centrifugation, employing linear denaturing sucrose gradients. Sucrose gradients (5-30%) were made in 0.1 M Tris-HCl (pH 7.5), 1 mM EDTA, 0.2% SDS and 50% (v/v) formamide. RNA samples in the same buffer were heated for 2 min at 55°C and cooled in ice before layering onto the gradients. Centrifugation was performed in a SW41 rotor at 15°C for 15 h at 85 OOOxg. Microinjection of RNA into Xenopus laevis oocytes Microinjection of RNA into Xenopus laevis oocytes was performed essentially according to Gurdon et al. (23) . Twenty five nl were injected of either total endothelial polyA RNA, size-fractionated endothelial polyA RNA, tobacco-mosaic virus (TMV) RNA or calf ca-crystalline RNA. All RNA preparations were adjusted to 1 mg/ml before injection. Microinjected oocytes were incubated for 30 h at 19°C in modified Barth's medium (23) . Subsequently, pools of 10 undamaged oocytes were homogenized in 0.25 ml 10 mM Tris-HCl (pH 9.0), 50 mM NaCl and centrifuged for 30 min in a microfuge.
Lipids were removed from the supernatant by two successive extractions with an equal volume of diethylether. The presence of vWF-like polypeptides was detected with an immunoradiometric assay.
Immunoradiometric assay (IRMA) for the detection of vWF-like products An immunoradiometric assay (IRMA) was used relying on Sepharose-linked monoclonal anti-human vWF CLB-RAg 20 and a mixture of six different 125I1 labeled anti-human vWF IgGs (CLB-RAg 20, CLB-RAg 23, CLB-RAg 35, CLB-RAg 38, CLB-RAg 56, CLB-RAg 58), representing 2x104 counts per min. The incubation conditions and washing procedures were as described (24) . The (25) . cDNA was size-fractionated employing Sepharose CL-4B chromatography and cDNA smaller than 600 bp was discarded. Typically, 600 ng of polyA RNA yielded approximately 200 ng size-fractionated, double-stranded "C-tailed" cDNA which was annealed to a twofold molar excess of G-tailed PstI-cleaved pUC9 (26) .
Transformation of strain E.coli DH1 (recA) was carried out by the high efficiency procedure of Hanahan (27) .
Screening on expression of vWF-like products in E.coli Duplicate filters, each carrying approximately 3000 colonies, were exposed for 20 min to an atmosphere saturated with vapor of chloroform (28) . Then, each filter was incubated separately for 16 h at room temperature in 20 ml 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 5 mM MgCl2, 0.1% Tween-20, 1 pg/ml pancreatic DNaseI and 40 pg/ml lysozyme under gentle agitation. Subsequently, the filters were rinsed in 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl (TS), carefully polished with tissue paper and rinsed again in TS. The filters were then incubated for 1 h at room temperature in TS containing 0.5% Tween-20, followed by a 10-min rinse in TS with 0.1% Tween-20. The incubation of fixed bacterial antigens with the first antibody preparation was for 1 h at room temperature, using a 1:500 dilution in TS, 0.1% Tween-20 of rabbit-anti-human vWF IgG which had been preabsorbed for 2 h at 4°C with a boiled extract of E.coli DH1 bacteria. After the antigen-antibody reaction, the filters were washed five times in TS, 0.1% Tween-20 and subsequently incubated for 1 h at room temperature with a 1:1000 dilution of horse-antirabbit IgG conjugated to horse-radish peroxidase. Finally, the filters were washed five times with TS, 0.1% Tween-20, followed by one wash step in TS, 0.5% Tween-20 and stained for peroxidase activity.
In-situ immunostaining of plasma proteins SDS-agarose electrophoresis and fixation was performed as described (29) except that a 2.5% agarose gel was used. Subsequently, the gel was incubated for at least 1 h at room temperature in TS, 3% bovine serum albumin, 0.1% gelatin, 0.6% human IgG, 0.05% Tween-20, 0.02% (w/v) sodium azide and then incubated for 16 h at room temperature with 1 pg/ml of the murine anti-human vWF IgG CLB-RAg 41. This incubation was followed by extensive washing of the gel for 1 h in 0.5 M NaCl and for 8 h in TS, respectively. Antigen-antibody complexes are detected after incubation for 16 h at room temperature with 125I-labeled goat-anti-mouse IgG, which was affinity-purified on a column containing covalently bound murine IgG. Subsequently, the gel was washed extensively as described above. Finally, the gel was dried and autoradiography was performed. Immunoblotting of bacterial proteins The analysis by immunoblotting of bacterial proteins was done after SDSpolyacrylamide gel electrophoresis according Lo Laemmli (30) and transfer of proteins from the gel into nitrocellulose membrane filters essentially as done before (31) . Bacterial extracts were prepared as described (32) . Finally, the proteins were solubilized in 0.5 ml loading buffer (30), heated for 5 min at 1000C and directly loaded onto the gel (25 p1 per slot). Polypeptides blotted on nitrocellulose filters were incubated with a 1:400 dilution of affinity-purified rabbit polyclonal anti-human vWF IgG or separately with 21 different murine monoclonal anti-human vWF IgG's (1 pg/ ml). Immunocomplexes were detected either with 125I-labeled sheep-antirabbit IgG or 125I-labeled affinity-purified goat-anti-mouse IgG (2x106 counts per min). Incubation, blocking of the filters and washing was the same procedure as described for colony-screening in a previous paragraph, except that for these blots 0.2% gelatin was added to all buffers and for the screening with monoclonals, the blots were finally washed for 16 h with 50 mM Tris-HCl (pH 7.5), 0.5% Tween-20, 0.5 M NaCl, 0.2% gelatin.
After washing, autoradiography was performed. Materials Immunoreagents were either from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service or from Dakopatts (Copenhagen, Denmark). "Super" reverse transcriptase was obtained from Anglia Biotechnology (UK), whereas restriction endonucleases were from New England Biolabs and used according to the manufacturers' instructions. Monoclonal antibodies were purified from ascites by absorption to a protein-A Sepharose column (Pharmacia Fine Chemicals, Uppsala, Sweden). 125I-labeling of polyclonal IgG was carried out by the chloramine-T method, whereas monoclonal IgG preparations were radiolabeled using the Iodogen reaction.
RESULTS

Identification of vWF-mRNA in endothelial cells
We intend to study the structure and function of human endothelial proteins involved in hemostasis and thrombosis. For that purpose, we have constructed cDNA clones, programmed by endothelial polyA RNA. In this paper, we focus on the construction and isolation of vWF-cDNA clones.
The substrate for these cDNA clones, vWF-mRNA, was identified in endo- polyA RNA preparations contain mRNA which encode vWF-like polypeptides. We repeated the experiment described above with polyA RNA size-fractionated by sucrose/formamide centrifugation which technique allows a more reliable RNA length determination than urea-agarose electrophoresis (33) . Essentially, the same results were obtained as for polyAt RNA size-fractionated by urea-agarose gel electrophoresis. Only products derived from polyA RNA with a length of 7500 to 10 000 nucleotides bound significantly more 125I. labeled monoclonal anti-vWF IgG than control mRNA. This result is in accord with the observation that the precursor protein for the vWF subunit has a molecular weight of approximately 260 000 daltons (8) . Fifteen per cent of the molecular weight of this glycoprotein is accounted for by carbohydrate residues (34) . Hence, the coding region required should comprise at least 6000 nucleotides.
Construction and isolation of vWF-cDNA clones
The availability of well-characterized polyclonal and monoclonal anti-vWF antibodies (35) allowed us to use a technique for screening bacterial colonies based on the expression of antigenic determinants (28) . For that purpose, we constructed a human endothelial cDNA library, using E.coli as a host and plasmid pUC9 as vector (26) . pUC9 contains the lac promotor, the translational initiation signals and 5 N-terminal aminoacids of 0-galactosidase, followed by multiple unique cloning sites (e.g. PstI). An expression library of 60 000 independent colonies was constructed of which approximately 90% contained plasmids with cDNA insertions with a length longer than 600 bp. This library was screened for bacterial synthesis of vWF-like proteins. After lysis of the colonies, the bacterial proteins were incubated with a rabbit polyclonal anti-human vWF IgG preparation and subsequently with sheep-anti-rabbit IgG conjugated with horse-radish peroxidase. This enzyme-linked immunosorbent assay (ELISA) revealed eight colonies which were positive on duplicate filters. An example is given in Fig. 2 . Rescreening consistently yielded positive signals. Moreover, rescreening with an affinity-purified rabbit polyclonal anti-human vWF IgG prepared from a different serum gave identical results. It should be noted that two colonies reacted strongly in the ELISA, two colonies gave an intermediate signal, whereas the remaining four colonies reacted weaker in the ELISA.
An analysis of plasmid DNA from these eight immunoreactive clones showed that the length of the DNA insertions ranged from 750 to 1415 bp. Clones which reacted weakly in the screening appeared to be similar, based on re- Figure 2 . Immunological detection of a vWF-cDNA clone. Colonies on duplicate filters were screened with rabbit-anti-human vWF IgG, followed by incubation with horse-anti-rabbit IgG conjugated with horse-radish peroxidase after which reactions the filters were stained for peroxidase activity. A detailed procedure is given in Materials and Methods. The positive colony on the duplicate filters (indicated by the arrow) contained a plasmid with a 1210 bp cDNA insertion. The crosses on the filters are marking the orientation. striction endonuclease analysis. The cDNA insertions of these clones all spanned approximately 1415 bp. In contrast, the remaining clones contained plasmid DNA with insertions which were different in length, namely 750, 780, 830 and 1210 bp. These plasmids will be referred to as pvWF 750, pvWF780, etc. By Southern blot analysis of restricted pvWF-DNA preparations, using restriction fragments of different insertions as probes, it was shown that all vWF-cDNA insertions consist of overlapping nucleotide sequences.
The vWF-like proteins, synthesized by the two strong expression clones pvWF1210 and pvWF780, were characterized by immunoblotting using an affinity-purified rabbit polyclonal anti-human vWF IgG preparation. The results, given in Fig. 3A , show that these two plasmids encode different discrete vWF-like proteins. Plasmid pvWFl210 codes for a product with a Mr of 37 000, whereas plasmid pvWF780 codes for a product with a M of 20 000. A schematic representation of the length and composition of these two vWFcDNA inserts and the encoded proteins is presented in Fig. 4 a single mRNA species of about 9000 nucleotides hybridizes to the vWF-cDNA probe. The length of this mRNA is in accord with the estimated coding segment of approximately 6000 nucleotides and is in agreement with the results of the vWF-mRNA identification experiment shown in Fig. 1 .
Part of the DNA sequence of the cDNA insertion of plasmid pvWF1210 has been determined, employing the dideoxytriphosphate chain termination method (16) . Hereto, the 260 bp PstI-cDNA fragment of pvWF1210 has been subcloned into M13mp9 DNA in both orientations and the DNA sequence of both strands has been clarified. The data are given in Fig. 6 . The 260 bp PstI-cDNA fragment is flanked by PstI-cDNA fragments of 770 and 180 bp, respectively. This conclusion has been drawn from the finding that the 770 and the 180 bp fragments harbor a 10-20 G-C stretch, created by terminal transferase, at one terminus, in contrast to the 260 bp fragment (data not shown). Restriction-enzyme mapping was used to establish i) that the 770 bp fragment is located upstream of the adjacent 260 bp fragment, whereas the 180 bp fragment is downstream, and ii) the orientation of the 260 bp fragment relative to the other PstI vWF-cDNA fragments. Inspection of possible reading frames revealed the following characteristics. Two reading frames Lack of discordancy demonstrates chromosome assignment. Two different Chinese-hamster cell lines, designated A3 and E36, have been used for the construction of the hybrids. These two cell lines exhibit a TaqI polymorphism with this probe which is illustrated by three crosshybridizing hamster fragments (lanes 1-7) and two hamster fragments (lanes 8-10), respectively. In addition, four human-specific TaqI fragments of 1.5, 2.2, 3.1 and 3.6 kb are seen in HeLa DNA (lane 11). The 3.6-kb fragment has the same size as one of the detected Chinese-hamster fragments. Consequently, this fragment could not be identified in DNA from hybrids derived from the Chinese-hamster cell line containing this fragment. Taken this into account, the human TaqI fragments are seen in lanes 2, 4, 5 and 10. None of the human-specific TaqI fragments mentioned are present in the lanes 3, 6, 7, 8 and 9. Similar results were found with DNA digested with other restriction endonucleases. As shown in Fig. 7B , the same results were also obtained after hybridization of the blot shown in Fig. 7A with the 260 bp PstI vWF-cDNA fragment of pvWF1210. In this way, a single fragment of approximately 4.2 kb, present in human DNA, hybridized to the probe, whereas no fragment in Chinese-hamster DNA was detected.
All the results from the Southern blot-analysis studies are summarized in Table 1 and show that the vWF cDNA hybridizes exclusively to DNA from human chromosome 12. DISCUSSION In this paper, we report on the construction and isolation of cDNA clones which encode part of the human vWF subunit of the factor VIII-von Willebrand factor complex. The availability of well-characterized polyclonal and monoclonal anti-vWF antibodies allowed us to screen on expression of antigenic determinants in E.coli cells. Several lines of evidence have been used to show that these overlapping cDNA insertions correspond to coding regions for the vWF protein, namely:
( i ) The expressed antigens are recognized by two different polyclonal anti-vWF sera, one of which had been affinity-purified on a column containing covalently bound factor VIII-von Willebrand factor.
( ii) Well-characterized monoclonal anti-vWF IgG (CLB-RAg 41) reacted with the expressed vWF-like polypeptides of a number of the immunoreactive clones, indicating that antigenic determinant(s) present on these bacterial products and on native vWF are identical. (iii) The cDNA-containing plasmids specifically hybridize with an endothelial mRNA with a length of about 9000 nucleotides. The length of this mRNA is sufficient to encode this glycoprotein with a molecular weight of 260 000 daltons. mRNA with a corresponding size also provokes the synthesis of vWF-like polypeptides in an in-vivo translation assay (Fig. 1) . From these results, we conclude that we have cloned part of the human vWF cDNA. This conclusion has been confirmed by the data of Titani and coworkers who have determined the aminoacid sequence of the carboxy-terminal cyanogen-bromide-cleaved fragment of native vWF (personal communication). Their sequence of 11 aminoacids is identical with our predicted carboxyterminal aminoacid sequence, shown in Fig. 6 . This also indicates that the vWF precursor protein is not extended at its carboxy-terminus.
We have shown that the use of monoclonal antibodies can provide a rapid and convenient way to confirm the presence of, or to identify a foreign gene segment expressed in bacteria. However, it should be noted that both polyclonal and monoclonal antibody preparations used in such experiments must have sufficient affinity to reveal 0.1-1 ng of antigen synthesized in a bacterial colony and should display a low background with E.coli lysate. A comparison of the signal produced by the two strong expression clones, containing pvWF780 or pvWF1210 with a standard series of spotted native vWF, showed that the colony signal corresponds to about 2 ng of vWF-like protein. From these data, it can be calculated that approximately 6x104 vWF-like molecules are synthesized per bacterium, whereas the clone harboring pvWF1210 produces about twofold less. We have not explored the reason for the different levels of expression of the vWF clones. In particular, four clones could be detected only by colony-screening, but not by iumunoblotting. Possibly in these cases, the vWF-like bacterial product is unstable.
We have determined, both by electrophoresis in formaldehyde-agarose gels and after denaturation of the RNA with glyoxal and dimethyl sulfoxide, that vWF-mRNA spans about 9000 nucleotides. The coding region required for a glycoprotein of 260 000 daltons, containing 15% carbohydrate residues, will be approximately 6000 bp. Preliminary sequence analysis indicates that vWF-mRNA contains a relatively short 3'-untranslated region of about 130 nucleotides, followed by a polyA-tail of 85 residues. Hence, it is conceivable that the actual vWF precursor protein is considerably larger than 260 000 daltons, provided that vWF-mRNA does not harbor an extensive 5'-untranslated region. Presently, we are attempting to clarify this point.
Screening the cDNA library, under stringent hybridization and washing conditions, with the fully codogenic 770 bp PstI cDNA fragment of pvWF1210 revealed 40 hybridizing colonies, including the eight immunoreactive ones. it is conceivable that those 32 novel clones contain vWF-cDNA insertions which are either in the opposite orientation versus the lac promotor or are not positioned in the reading frame of the N-terminal aminoacids of n-galactosidase. The longest "non-expression" clone so far examined appeared to harbor a plasmid with a cDNA insertion of 2280 bp. Southern blot analysis confirmed that the insertions consist of vWF cDNA. Thus, pvWF plasmid-containing clones represent only 0.07% of the entire endothelial cDNA library, in spite of the fact that cDNA smaller than 600 bp has been discarded. Using labeled vWF-cDNA probes and a series of human-hamster and humanmouse somatic-cell hybrids conLaining reduced numbers of human chromosomes, we have been able to assign the human vWF gene exclusively to chromosome 12. Hybridization of restricted DNA of different hybrids with the 770 bp vWFcDNA probe resulted in the same set of human fragments for each restriction endonuclease used. Only one TaqI-restriction fragment is detected with the 260 bp vWF-cDNA probe. Hence, it is likely that there is only one copy of the vWF gene present in the human genome. Based upon an immunological approach, Kefalides (37) concluded that the vWF gene may be located on human chromosome 5. To correlate his results with those of Edgell et al. (38) who reported suppression of vWF expression in endothelial cell hybrids, he proposed that a particular combination of either human chromosomes or human plus rodent chromosomes is required for vWF to be expressed. That hypothetical combination might have been different in the hybrids used in those two studies. Hybridization of digested DNA from a panel of somatic-cell hybrids with a well-defined cDNA probe is apparently a more reliable tech-nique to map a gene than innunofluorescent methods. Our data clearly demonstrate that the vWF gene is not located on chromosome 5, but exclusively on chromosome 12.
Currently, we are constructing pvWF plasmids which extend into the 5' direction of vWF-mRNA. Assembly of a full-length vWF cDNA will enable us to study structure and function of the vWF protein.
